TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20354859

Group type: EXPERIMENTAL
Intervention: Diclofenac phonophoresis
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ultrasound therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo ultrasound therapy
Number of subjects: 60
Study: 19494795

Group type: EXPERIMENTAL
Intervention: NGX-4010 capsaicin patch (640 microg/cm2) applied for 60 minutes
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: NGX-4010 capsaicin patch (640 microg/cm2) applied for 90 minutes
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: NGX-4010 capsaicin patch (640 microg/cm2) applied on feet
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: NGX-4010 capsaicin patch (640 microg/cm2) with larger treatment areas
Number of subjects: 173
Study: 17185118

Group type: COMPARATOR
Intervention: Lidocaine with epinephrine (36 mg lidocaine + 18 mug epinephrine)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Lidocaine plus meperidine with epinephrine (36 mg lidocaine + 18 mug epinephrine + 36 mg meperidine + 18 mug epinephrine)
Number of subjects: 48
Study: 15794456

Group type: COMPARATOR
Intervention: 5% carbamide peroxide professional custom tray system
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 18% carbamide peroxide paint-on gel
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 1% hydrogen peroxide dentifrice with manganese gluconate activator
Number of subjects: 43
Study: 14700480

Group type: EXPERIMENTAL
Intervention: Oral bexarotene 300 mg/m2/day
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Oral bexarotene 600 mg/m2/day
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo (prior chemotherapy responders)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Oral bexarotene 300 mg/m2/day (prior chemotherapy responders)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Oral bexarotene 600 mg/m2/day (prior chemotherapy responders)
Number of subjects: 54
Study: 9643407

Group type: EXPERIMENTAL
Intervention: Primary surgery (total abdominal hysterectomy and bilateral salpingo-oophorectomy)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant therapy (radiotherapy and/or systemic chemotherapy)
Number of subjects: 19
Study: 7563044

Group type: EXPERIMENTAL
Intervention: Perceived behavioral control (PBC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low binge eaters
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High binge eaters
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group attendance
Number of subjects: 0
Study: 2789438

Group type: EXPERIMENTAL
Intervention: 15% polyvinylpyrrolidone (PVP) solution
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: 20% polyvinylpyrrolidone (PVP) solution
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: PVP (both concentrations)
Number of subjects: 123
Study: 269080

Group type: EXPERIMENTAL
Intervention: Chlorhexidine digluconate (0.1%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31796571

Group type: EXPERIMENTAL
Intervention: High-Intensity Intermittent Exercise (HIIE)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Exercise (MIE)
Number of subjects: 12
Study: 31579003

Group type: EXPERIMENTAL
Intervention: Radium-223 added to abiraterone acetate and prednisone or prednisolone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo added to abiraterone acetate and prednisone or prednisolone
Number of subjects: 0
Study: 28339098

Group type: EXPERIMENTAL
Intervention: Chemotherapy with concurrent cediranib and continued as maintenance
Number of subjects: 456

Group type: COMPARATOR
Intervention: Standard chemotherapy only
Number of subjects: 456
Study: 25666325

Group type: EXPERIMENTAL
Intervention: Right Ventricular Apical (RVA) pacing
Number of subjects: 145
Study: 23865654

Group type: EXPERIMENTAL
Intervention: Estrogen therapy (ET)
Number of subjects: 18601

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18601
Study: 21060206

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no EPO administration)
Number of subjects: 0
Study: 18068905

Group type: EXPERIMENTAL
Intervention: Contingency management (CM)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Noncontingent control
Number of subjects: 116
Study: 16604826

Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg daily for 5 days)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Clomiphene citrate (100 mg daily for 5 days)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 106

Group type: COMPARATOR
Intervention: Clomiphene citrate (CC)
Number of subjects: 106
Study: 12591062

Group type: EXPERIMENTAL
Intervention: Neomycin
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 10748791

Group type: EXPERIMENTAL
Intervention: Beta-blocker treatment (Bisoprolol)
Number of subjects: 0
Study: 2123239

Group type: EXPERIMENTAL
Intervention: Immediate treatment with penicillin V (10-day course starting at diagnosis)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Delayed treatment with penicillin V (10-day course starting after 48 hours)
Number of subjects: 113
Study: 6104858

Group type: EXPERIMENTAL
Intervention: tiapride (300 mg daily for 3-4 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: floctafenine (200 mg daily for 3-4 weeks)
Number of subjects: 30
Study: 30755154

Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic and resistance exercise
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-exercising group (control)
Number of subjects: 20
Study: 28174175

Group type: EXPERIMENTAL
Intervention: Online ECG monitoring education program and strategies to implement and sustain change in practice
Number of subjects: 3013

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 3013
Study: 27060951

Group type: EXPERIMENTAL
Intervention: Mindfulness Training (MT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Psychoeducation (PE)
Number of subjects: 14
Study: 25823177

Group type: EXPERIMENTAL
Intervention: Intralesional triamcinolone acetonide alone (Group A)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Triamcinolone acetonide + 5-fluorouracil (Group B)
Number of subjects: 150
Study: 21594650

Group type: EXPERIMENTAL
Intervention: darapladib
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: statin use
Number of subjects: 330

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 330
Study: 20638874

Group type: EXPERIMENTAL
Intervention: Melatonin infusion (50 mg IV during surgery) and oral melatonin (10 mg for 3 nights post-surgery)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo infusion and oral placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Melatonin treatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 50
Study: 18157888

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 15746463

Group type: EXPERIMENTAL
Intervention: Cilostazol 200 mg per day
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study: 15259400

Group type: EXPERIMENTAL
Intervention: Prospective memory training (PM training) consisting of errorless learning and spaced retrieval techniques taught in six sessions in subjects' homes.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untrained AD controls
Number of subjects: 0
Study: 10480207

Group type: EXPERIMENTAL
Intervention: Vigabatrin (GVG) therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no GVG)
Number of subjects: 24
Study: 7832130

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Follow-up after PTCA
Number of subjects: 207

Group type: COMPARATOR
Intervention: Comparison to CABG
Number of subjects: 207
Study: 2469451

Group type: EXPERIMENTAL
Intervention: Moclobemide (100, 200, and 300 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Deprenyl (10 mg)
Number of subjects: 8
Study: 6165144

Group type: EXPERIMENTAL
Intervention: Midodrine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31942627

Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir 800/100 mg q24h with rifampicin, escalated to darunavir/ritonavir 1600/200 mg q24h and 800/100 mg q12h.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir adjusted doses with rifampicin.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly mentioned).
Number of subjects: 28
Study: 31399138

Group type: EXPERIMENTAL
Intervention: Booklet self-help program with coaching (6 lessons over 8 weeks, 1-2 hours per week)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Attention-only control condition
Number of subjects: 200
Study: 28973683

Group type: EXPERIMENTAL
Intervention: Vitamin D (20,000 IU per week)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 26620289

Group type: EXPERIMENTAL
Intervention: Housing First with Assertive Community Treatment (ACT)
Number of subjects: 950
Study: 25432250

Group type: EXPERIMENTAL
Intervention: Indirect bonding procedure
Number of subjects: 64

Group type: COMPARATOR
Intervention: Direct bonding procedure
Number of subjects: 64
Study: 22572824

Group type: EXPERIMENTAL
Intervention: Long-acting octreotide (Sandostatin LAR®) depot 30 mg intramuscularly every month
Number of subjects: 33

Group type: COMPARATOR
Intervention: 0.9% sodium chloride (control)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Long-acting octreotide
Number of subjects: 33
Study: 20500927

Group type: EXPERIMENTAL
Intervention: 500 mg quercetin/d
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 1000 mg quercetin/d
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 17971108

Group type: EXPERIMENTAL
Intervention: Nicorette polacrilex gum (6 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 28
Study: 15655036

Group type: EXPERIMENTAL
Intervention: Evidence-based decision-making framework for obesity prevention
Number of subjects: 0
Study: 12433727

Group type: EXPERIMENTAL
Intervention: Selenium-enriched yeast supplementation (247 micro g selenium/day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 10527445

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Minilaparotomy cholecystectomy (MC)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 22
Study: 7669482

Group type: EXPERIMENTAL
Intervention: Fluparoxan (twice-daily for 5 1/2 days, 11 doses)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Clonidine (200 micrograms infused intravenously over 5 min)
Number of subjects: 16
Study: 2161038

Group type: EXPERIMENTAL
Intervention: WI79-9 vaccine (10^7.3 plaque-forming units/dose, 2 doses, 28 days apart)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: WI79-9 vaccine
Number of subjects: 77
Study: 6856679

Group type: EXPERIMENTAL
Intervention: Lateral method for an obtuse angle
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lateral method for an acute angle
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Over-the-joint method for an obtuse angle
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Over-the-joint method for an acute angle
Number of subjects: 40
Study: 31658903

Group type: EXPERIMENTAL
Intervention: Cervical carotid atherosclerosis
Number of subjects: 666

Group type: COMPARATOR
Intervention: Cardioembolic stroke
Number of subjects: 666
Study: 28961977

Group type: EXPERIMENTAL
Intervention: cART initiation
Number of subjects: 84
Study: 26421702

Group type: EXPERIMENTAL
Intervention: Intravenous 50 μg bolus of phenylephrine (Group P)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (Group S)
Number of subjects: 40
Study: 24300437

Group type: EXPERIMENTAL
Intervention: Experimental intervention to promote breastfeeding
Number of subjects: 13879

Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 13879

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 13879
Study: 22317042

Group type: EXPERIMENTAL
Intervention: Free navigation style
Number of subjects: 0

Group type: COMPARATOR
Intervention: Restricted navigation style
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulator sickness measurement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Balancing tests
Number of subjects: 0
Study: 19713403

Group type: EXPERIMENTAL
Intervention: Humidification therapy techniques (specific techniques not detailed in the abstract)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Preferred technology (specific technology not detailed in the abstract)
Number of subjects: 8
Study: 17823673

Group type: EXPERIMENTAL
Intervention: Ultrasonic system with polishing fluid containing hydroxylapatite granules
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ultrasonic system only
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Medium-hard toothbrush with polishing fluid
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Toothbrush only
Number of subjects: 30

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 30
Study: 14723988

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-trimethoprim-piperaquine (DHA-TP)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Artesunate-mefloquine (A3M)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine and DHA-TP
Number of subjects: 114
Study: 11535941

Group type: EXPERIMENTAL
Intervention: Clobazam and tramadol administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Experimental stress conditions (isolation, food and sleep deprivation, extreme temperatures)
Number of subjects: 0
Study: 9568465

Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Patients with Billroth II gastrojejunostomy
Number of subjects: 17
Study: 7817819

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at a dosage of 0.2 IU/kg/day for 3 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 30
Study: 3265378

Group type: EXPERIMENTAL
Intervention: Sulbactam/ampicillin 2g plus sulbactam 1g 3 times a day
Number of subjects: 23

Group type: COMPARATOR
Intervention: Cefotaxime 2g 3 times a day
Number of subjects: 23
Study: 29980162

Group type: EXPERIMENTAL
Intervention: Home based electrostimulation therapy (EST) with amplitude modulated current (base frequency of 4000 Hz, frequency band of 100–250 Hz) over 2 weeks adjuvant to a concurrent sinusitis therapy with topical corticosteroids
Number of subjects: 16
Study: 28118308

Group type: EXPERIMENTAL
Intervention: Low-pressure continuous BFR
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: High-pressure intermittent BFR
Number of subjects: 17

Group type: COMPARATOR
Intervention: Heavy-load resistance exercise (80% 1RM)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Light-load resistance exercise (20% 1RM)
Number of subjects: 17
Study: 26363574

Group type: EXPERIMENTAL
Intervention: Trapeziectomy with ligament reconstruction using a bone tunnel (Burton‐Pellegrini)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Tendon sling arthroplasty (Weilby)
Number of subjects: 79
Study: 23212807

Group type: EXPERIMENTAL
Intervention: High-dose risperidone (1.25 mg/day for 20 to <45 kg; 1.75 mg/day for >45 kg)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Low-dose risperidone (0.125 mg/day for 20 to <45 kg; 0.175 mg/day for >45 kg)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: High-dose risperidone
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Low-dose risperidone
Number of subjects: 96
Study: 21178989

Group type: EXPERIMENTAL
Intervention: 60 mg sustained-release dextroamphetamine (d-AMP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 18341945

Group type: EXPERIMENTAL
Intervention: Use of a recognized risk assessment chart
Number of subjects: 200

Group type: COMPARATOR
Intervention: No use of a recognized risk assessment chart
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Use of a patient information sheet
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Previous peripheral angioplasty
Number of subjects: 200
Study: 15515137

Group type: EXPERIMENTAL
Intervention: Seemingly unrelated regression equations with inverse probability weighting for parameter estimation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Survival time
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality-adjusted survival time
Number of subjects: 0
Study: 12713240

Group type: EXPERIMENTAL
Intervention: Foreknowledge of the target's color
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preview presentations with target sharing color with a single colored set of previewed letters
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Removing similarity across displays
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assessment of probability effects of target color
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhibitory carryover from a preview color group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anticipatory set for a known target color
Number of subjects: 0
Study: 10320186

Group type: EXPERIMENTAL
Intervention: Sevoflurane (0.2% or 0.4% end-tidal) + Nitrous oxide (30% end-tidal)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sevoflurane (0.2% or 0.4% end-tidal)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (30% end-tidal)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (30% end-tidal) + Sevoflurane (0.2% or 0.4% end-tidal)
Number of subjects: 20
Study: 8907100

Group type: EXPERIMENTAL
Intervention: Quit kit plus 1 telephone counseling session
Number of subjects: 3030

Group type: EXPERIMENTAL
Intervention: Quit kit plus up to 6 telephone counseling sessions
Number of subjects: 3030

Group type: COMPARATOR
Intervention: Self-help quit kit
Number of subjects: 3030
Study: 1986555

Group type: EXPERIMENTAL
Intervention: Corticosteroids (15-day tapering dose of prednisone: 15, 10, 5 mg) with diuretics (40 mg furosemide and 200 mg spironolactone)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (diuretics only: 40 mg furosemide and 200 mg spironolactone)
Number of subjects: 37
Study: 6851752

Group type: EXPERIMENTAL
Intervention: Orthograde bowel lavage alone (group I)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Combined bowel lavage and parenteral antibiotic prophylaxis with 4 gm Cefoxitin (group II)
Number of subjects: 57
Study: 30922846

Group type: EXPERIMENTAL
Intervention: Major hepatectomy in high-risk group
Number of subjects: 359

Group type: COMPARATOR
Intervention: Minor hepatectomy in high-risk group
Number of subjects: 359

Group type: COMPARATOR
Intervention: Extent of hepatectomy in low-risk group
Number of subjects: 359
Study: 29079060

Group type: EXPERIMENTAL
Intervention: n‐3 polyunsaturated fatty acids (PUFA) supplementation (2.2g/d of EPA and DHA)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 29
Study: 27049404

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 115

Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 115
Study: 24325899

Group type: EXPERIMENTAL
Intervention: THUNDERBEAT (TB)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard electrosurgery (SES)
Number of subjects: 50
Study: 22256909

Group type: EXPERIMENTAL
Intervention: loteprednol etabonate 0.5%/tobramycin 0.3% (LE/T)
Number of subjects: 308

Group type: COMPARATOR
Intervention: dexamethasone 0.1%/tobramycin 0.3% (DM/T)
Number of subjects: 308
Study: 20332140

Group type: EXPERIMENTAL
Intervention: Triplet chemotherapy
Number of subjects: 443

Group type: COMPARATOR
Intervention: Standard doublet regimen
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: ERCC1-negative status and adenocarcinomas
Number of subjects: 443
Study: 16621113

Group type: EXPERIMENTAL
Intervention: Telecare Group (TG) - 12 appointments (9 telematic with GlucoBeep system + 3 ambulatory)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional Group (CG) - 12 outpatient appointments
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cost analysis for TG
Number of subjects: 40
Study: 12687877

Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Radiofrequency (RF) procedures
Number of subjects: 32
Study: 10924317

Group type: EXPERIMENTAL
Intervention: Dofetilide (8 microg. kg(‐1))
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Amiodarone (5 mg. kg(‐1))
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 8825017

Group type: EXPERIMENTAL
Intervention: Broad spectrum antioxidant capsule (po BID)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 1402964

Group type: EXPERIMENTAL
Intervention: Carbamazepine for six or 24 months
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Phenytoin for six or 24 months
Number of subjects: 276

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 276
Study: 2998191

Group type: EXPERIMENTAL
Intervention: 37.5 mg of terodiline daily for two 3-week periods
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Long-term terodiline treatment (6 months to 3 years)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Terodiline treatment
Number of subjects: 24
Study: 30058839

Group type: EXPERIMENTAL
Intervention: 5-mg axitinib
Number of subjects: 72

Group type: COMPARATOR
Intervention: 400-mg sorafenib
Number of subjects: 72
Study: 29164749

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) of calf muscles, twice a week for six weeks (3 × 6 stimulation trains at 30 Hz above individual cramp threshold frequency)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control leg (unstimulated)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) of calf muscles
Number of subjects: 19